Floatz logo

Pegcetacoplan

Ovarian Carcinosarcoma

Roswell Park Cancer Instituteprotein_peptidePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

19 Active assets in the Ovarian Carcinosarcoma cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
Mayo Clinic
Phase 2BB
CIS-DIAMMINEDICHLOROPLATINUM II
National Cancer Institute (NCI)
Phase 2BB
Carboplatin
University of Oklahoma
Phase 3BB
Multi-Epitope Folate Receptor Alpha-Loaded Dendritic Cell Vaccine
Mayo Clinic
Phase 2B
Pembrolizumab
Mayo Clinic
Phase 2B

View all 35 →

Same molecule, other indications

Pegcetacoplan is also rated in:

fallopian tube clear cell adenocarcinomaDormant
CCC
Indicative ·
53 / 100
View asset →
fallopian tube endometrioid adenocarcinomaDormant
CCC
Indicative ·
53 / 100
View asset →
fallopian tube carcinosarcomaDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →